Canada Life’s Coherus Oncology CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-11,699
| Closed | -$39K | – | 2142 |
|
|
2023
Q4 | $39K | Sell |
11,699
-58,193
| -83% | -$156K | ﹤0.01% | 2059 |
|
|
2023
Q3 | $261K | Sell |
69,892
-42,197
| -38% | -$195K | ﹤0.01% | 1814 |
|
|
2023
Q2 | $478K | Buy |
112,089
+25,948
| +30% | +$153K | ﹤0.01% | 1698 |
|
|
2023
Q1 | $590K | Sell |
86,141
-2,731
| -3% | -$21.2K | ﹤0.01% | 1667 |
|
|
2022
Q4 | $704K | Buy |
88,872
+3,446
| +4% | +$26.5K | ﹤0.01% | 1626 |
|
|
2022
Q3 | $821K | Buy |
85,426
+22,491
| +36% | +$228K | ﹤0.01% | 1559 |
|
|
2022
Q2 | $456K | Buy |
62,935
+8,650
| +16% | +$75.2K | ﹤0.01% | 1698 |
|
|
2022
Q1 | $719K | Hold |
54,285
| – | – | ﹤0.01% | 1621 |
|
|
2021
Q4 | $866K | Sell |
54,285
-2,616
| -5% | -$45.7K | ﹤0.01% | 1574 |
|
|
2021
Q3 | $921K | Hold |
56,901
| – | – | ﹤0.01% | 1552 |
|
|
2021
Q2 | $787K | Buy |
56,901
+2,827
| +5% | +$40K | ﹤0.01% | 1609 |
|
|
2021
Q1 | $790K | Sell |
54,074
-7,364
| -12% | -$125K | ﹤0.01% | 1597 |
|
|
2020
Q4 | $1.07M | Sell |
61,438
-6,012
| -9% | -$107K | ﹤0.01% | 1479 |
|
|
2020
Q3 | $1.24M | Sell |
67,450
-7,444
| -10% | -$138K | ﹤0.01% | 1311 |
|
|
2020
Q2 | $1.33M | Buy |
74,894
+71,300
| +1,984% | +$1.21M | ﹤0.01% | 1274 |
|
|
2020
Q1 | $58K | Hold |
3,594
| – | – | ﹤0.01% | 2085 |
|
|
2019
Q4 | $64K | Buy |
+3,594
| New | +$66.3K | ﹤0.01% | 2182 |
|
|
2019
Q3 | – | Sell |
-6,774
| Closed | -$149K | – | 1342 |
|
|
2019
Q2 | $149K | Buy |
6,774
+3,374
| +99% | +$58.6K | ﹤0.01% | 2101 |
|
|
2019
Q1 | $46K | Hold |
3,400
| – | – | ﹤0.01% | 2269 |
|
|
2018
Q4 | $30K | Hold |
3,400
| – | – | ﹤0.01% | 2489 |
|
|
2018
Q3 | $56K | Hold |
3,400
| – | – | ﹤0.01% | 2365 |
|
|
2018
Q2 | $47K | Hold |
3,400
| – | – | ﹤0.01% | 2412 |
|
|
2018
Q1 | $37K | Hold |
3,400
| – | – | ﹤0.01% | 2422 |
|
|
2017
Q4 | $30K | Hold |
3,400
| – | – | ﹤0.01% | 2450 |
|
|
2017
Q3 | $46K | Hold |
3,400
| – | – | ﹤0.01% | 2352 |
|
|
2017
Q2 | $49K | Hold |
3,400
| – | – | ﹤0.01% | 2324 |
|
|
2017
Q1 | $72K | Hold |
3,400
| – | – | ﹤0.01% | 2206 |
|
|
2016
Q4 | $96K | Hold |
3,400
| – | – | ﹤0.01% | 2125 |
|
|
2016
Q3 | $91K | Hold |
3,400
| – | – | ﹤0.01% | 2170 |
|
|
2016
Q2 | $57K | Hold |
3,400
| – | – | ﹤0.01% | 2269 |
|
|
2016
Q1 | $72K | Hold |
3,400
| – | – | ﹤0.01% | 1970 |
|
|
2015
Q4 | $78K | Hold |
3,400
| – | – | ﹤0.01% | 1923 |
|
|
2015
Q3 | $68K | Buy |
+3,400
| New | +$103K | ﹤0.01% | 1944 |
|
Other funds holding CHRS
RCMNY
KKRC
Canada Life's CHRS Position: Q1 2024 in Review
Canada Life sold out of Coherus Oncology (CHRS) in Q1 2024, closing a stake of 11,699 shares — an estimated $39K sold.
Canada Life first reported a position in CHRS in Q3 2015 and held it in 33 quarters. The position peaked at $1.33M in Q2 2020. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.
- Canada Life reported no remaining Coherus Oncology position as of Q1 2024 after selling out during the quarter.
- Canada Life sold 11,699 Coherus Oncology shares in Q1 2024, an estimated $39K.
- Canada Life first reported a position in Coherus Oncology in Q3 2015 and held it in 33 quarters.
- Canada Life's Coherus Oncology position peaked at $1.33M in Q2 2020.
- 137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.
Based on Canada Life's 13F filing for Q1 2024, filed 13 May 2024.